Restless legs syndrome - Current therapies and management of augmentation

Nature Reviews Neurology

Volumn 11, Issue 8, 2015, Pages 434-445

  Trenkwalder, Claudia ^a,b   Winkelmann, Juliane ^d,e   Inoue, Yuichi ^b,f   Paulus, Walter ^c  

^a Paracelsus Elena Klinik Kassel   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c STANFORD UNIVERSITY   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; FERROCARBOXYMALTOSE; GABAPENTIN; GABAPENTIN ENACARBIL; IRON; IRON DERIVATIVE; IRON SACCHARATE; LEVODOPA; NALOXONE PLUS OXYCODONE; PLACEBO; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ADDICTION; APPLICATION SITE REACTION; BEDTIME DOSAGE; CLINICAL PRACTICE; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; EUROPE; EVENING DOSAGE; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; IMPULSE CONTROL DISORDER; IRON DEFICIENCY; JAPAN; LONG TERM CARE; NAUSEA; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SKIN REDNESS; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; TRANSDERMAL PATCH; TREATMENT FAILURE; UNITED STATES; UNSTEADINESS; UREMIA; DEFICIENCY; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; PREGNANCY COMPLICATIONS;

AMINES; ANALGESICS, OPIOID; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOPAMINE AGONISTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; IRON; IRON COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; PREGABALIN; PREGNANCY; PREGNANCY COMPLICATIONS; RESTLESS LEGS SYNDROME;

EID: 84938966227     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.122     Document Type: Review

References (109)

1. Allen, R. P. et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 4, 101-119 (2003).
2. Allen, R. P. et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance. Sleep Med. 15, 860-873 (2014).
3. Szentkirályi, A., Völzke, H., Hoffmann, W., Trenkwalder, C. & Berger, K. Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. Neurology 82, 2026-2033 (2014).
4. Trenkwalder, C. et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov. Disord. 14, 102-110 (1999).
5. Scholz, H. et al. Dopamine agonists for the treatment of restless legs syndrome. Cochrane Database of Systematic Reviews, Issue 3, Art. No.: CD006009. http://dx.doi.org/10.1002/14651858.CD006009.pub2.
6. Scholz, H. et al. Levodopa for restless legs syndrome. Cochrane Database of Systematic Reviews, Issue 2, Art. No.: CD005504. http://dx.doi.org/10.1002/14651858.CD005504.pub2.
7. Roth, T., Arnold, L. M., Garcia-Borreguero, D., Resnick, M. & Clair, A. G. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med. Rev. 18, 261-271 (2014).
8. Garcia-Borreguero, D. et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 74, 1897-1904 (2010).
9. Trenkwalder, C. et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 12, 1141-1150 (2013).
10. Giannaki, C. D. et al. A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol. Dial. Transplant. 28, 2834-2840 (2013).
11. Giannaki, C. D. et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol. 14, 194 (2013).
12. Mortazavi, M. et al. Aerobic exercise improves signs of restless leg syndrome in end stage renal disease patients suffering chronic hemodialysis. ScientificWorldJournal 2013, 628142 (2013).
13. Heide, A. C. et al. Effects of transcutaneous spinal direct current stimulation in idiopathic restless legs patients. Brain Stimul. 7, 636-642 (2014).
14. Trenkwalder, C. et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov. Disord. 23, 2267-2302 (2008).
15. Hornyak, M. et al. What treatment works best for restless legs syndrome? Meta-Analyses of dopaminergic and non-dopaminergic medications. Sleep Med. Rev. 18, 153-164 (2014).
16. Garcia-Borreguero, D. et al. The long-Term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 14, 675-684 (2013).
17. Walters, A. S. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov. Disord. 10, 634-642 (1995).
18. Walters, A. S. et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 4, 121-132 (2003).
19. Trenkwalder, C. et al. Clinical trials in restless legs syndrome-recommendations of the European RLS Study Group (EURLSSG). Mov. Disord. 22 (Suppl. 18), S495-S504 (2007).
20. Walters, A. S. et al. Review of severity rating scales for restless legs syndrome: critique and recommendations. Mov. Disord. Clin. Practice 1, 317-324 (2014).
21. Kohnen, R, Stiasny-Kolster, K, Oertel, W. H., Benes, H. & Trenkwalder, C. Severity rating of restless legs syndrome: validation of the RLS-6 scales [abstract]. Sleep 27 (Abstract Suppl.), A342 (2004).
22. Trenkwalder, C. et al. l-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 18, 681-688 (1995).
23. García-Borreguero, D. et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 8, 520-530 (2007).
24. Allen, R. P. et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N. Engl. J. Med. 370, 621-631 (2014).
25. Högl, B. et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 12, 351-360 (2011).
26. Oertel, W. et al. Long-Term safety and efficacy of rotigotine transdermal patch for moderate-To-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 10, 710-720 (2011).
27. Garcia-Borreguero, D. et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59, 1573-1579 (2002).
28. Kushida, C. A. et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 72, 439-446 (2009).
29. Kushida, C. A. et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 32, 159-168 (2009).
30. Inoue, Y. et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr. Med. Res. Opin. 29, 13-21 (2013).
31. Inoue, Y., Uchimura, N., Kuroda, K., Hirata, K. & Hattori, N. Long-Term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 251-257 (2012).
32. Walters, A. S. et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 16, 327-332 (1993).
33. Allen, R. P., Auerbach, S., Bahrain, H., Auerbach, M. & Earley, C. J. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am. J. Hematol. 88, 261-264 (2013).
34. Grote, L., Leissner, L., Hedner, J. & Ulfberg, J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov. Disord. 24, 1445-1452 (2009).
35. Allen, R. P. et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 12, 906-913 (2011).
36. Mehmood, T., Auerbach, M., Earley, C. J. & Allen, R. P. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). Sleep Med. 15, 1473-1476 (2014).
37. Earley, C. J. et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med. 10, 206-211 (2009).
38. Schulte, E. C., Gross, N., Slawik, H. & Winkelmann, J. When restless legs syndrome turns malignant. Sleep Med. 14, 575-577 (2013).
39. Hornyak, M. et al. Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial. J. Neurol. Neurosurg. Psychiatry 79, 823-825 (2008).
40. Becker, P. M. & Sharon, D. Mood disorders in restless legs syndrome (Willis-Ekbom disease). J. Clin. Psychiatry 75, e679-e694 (2014).
41. Aurora, R. N. et al. Update to the AASM Clinical Practice Guideline: "The treatment of restless legs syndrome and periodic limb movement disorder in adults-An update for 2012: practice parameters with an evidence-based systematic review and meta-Analyses". Sleep 35, 1037 (2012).
42. Garcia-Borreguero, D. et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur. J. Neurol. 19, 1385-1396 (2012).
43. Trenkwalder, C. et al. One-year treatment with standard and sustained-release levodopa: appropriate long-Term treatment of restless legs syndrome? Mov. Disord. 18, 1184-1189 (2003).
44. Högl, B. et al. Progressive development of augmentation during long-Term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J. Neurol. 257, 230-237 (2010).
45. Inoue, Y. et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 326-333 (2013).
46. Silber, M. H. et al. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin. Proc. 88, 977-986 (2013).
47. Allen, R. P. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment. Int. Rev. Psychiatry 26, 248-262 (2014).
48. Manconi, M. et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med. 8, 491-497 (2007).
49. Nardone, R. et al. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurol. Scand. 114, 244-249 (2006).
50. Tergau, F., Wischer, S. & Paulus, W. Motor system excitability in patients with restless legs syndrome. Neurology 52, 1060-1063 (1999).
51. Trenkwalder, C. et al. Efficacy of rotigotine for treatment of moderate-To-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 7, 595-604 (2008).
52. Walters, A. S. et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov. Disord. 19, 1414-1423 (2004).
53. Trenkwalder, C. et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry 75, 92-97 (2004).
54. Winkelman, J. W. et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67, 1034-1039 (2006).
55. Oertel, W. H. et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov. Disord. 22, 213-219 (2007).
56. Ferini-Strambi, L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 3 (Suppl.), S23-S25 (2002).
57. Ferini-Strambi, L. et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 9, 874-881 (2008).
58. Jama, L. et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med. 10, 630-636 (2009).
59. Inoue, Y. et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: a polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med. 11, 11-16 (2010).
60. Ma, J. F. et al. Efficacy and safety of pramipexole in Chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial. Sleep Med. 13, 58-63 (2012).
61. Ferri, R. et al. Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep. Sleep Med. 13, 529-535 (2012).
62. Manconi, M. et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Mov. Disord. 26, 892-895 (2011).
63. Sun, Y., van Valkenhoef, G. & Morel, T. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-To-severe restless legs syndrome. Curr. Med. Res. Opin. 30, 2267-2278 (2014).
64. Miranda, C. M. Transdermal rotigotine in the treatment of restless legs patients who develop augmentation of symptoms [Spanish]. Rev. Med. Chil. 141, 407-408 (2013).
65. Walters, A. S. et al. Review of diagnostic instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations. J. Clin. Sleep Med. 10, 1343-1349 (2014).
66. Lipford, M. C. & Silber, M. H. Long-Term use of pramipexole in the management of restless legs syndrome. Sleep Med. 13, 1280-1285 (2012).
67. Tagaya, H. et al. Pergolide restores sleep maintenance but impairs sleep EEG synchronization in patients with restless legs syndrome. Sleep Med. 3, 49-54 (2002).
68. Voon, V. et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 11, 117 (2011).
69. Moore, T. J., Glenmullen, J. & Mattison, D. R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174, 1930-1933 (2014).
70. Papazisis, G. & Tzachanis, D. Pregabalin's abuse potential: a mini review focusing on the pharmacological profile. Int. J. Clin. Pharmacol. Ther. 52, 709-716 (2014).
71. Saletu, M. et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J. Neural Transm. 117, 463-473 (2010).
72. Ellenbogen, A. L. et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin. Neuropharmacol. 34, 8-16 (2011).
73. Kume, A. Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose? Neuropsychiatr. Dis. Treat. 10, 249-262 (2014).
74. Sommer, M. et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol. Scand. 115, 347-350 (2007).
75. Allen, R. et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 11, 512-519 (2010).
76. Garcia-Borreguero, D. et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 37, 635-643 (2014).
77. Ondo, W. G. Restless legs syndrome: pathophysiology and treatment. Curr. Treat. Options Neurol. 16, 317 (2014).
78. Ondo, W. G. Methadone for refractory restless legs syndrome. Mov. Disord. 20, 345-348 (2005).
79. Silver, N., Allen, R. P., Senerth, J. & Earley, C. J. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 12, 440-444 (2011).
80. Walters, A. S. et al. Long-Term follow-up on restless legs syndrome patients treated with opioids. Mov. Disord. 16, 1105-1109 (2001).
81. Manconi, M. et al. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann. Neurol. 71, 834-844 (2012).
82. Howell, M. J. & Schenck, C. H. Restless nocturnal eating: a common feature of Willis-Ekbom Syndrome (RLS). J. Clin. Sleep Med. 8, 413-419 (2012).
83. Tzonova, D. et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease). Sleep Med. 13, 151-155 (2012).
84. Comella, C. L. Treatment of restless legs syndrome. Neurotherapeutics 11, 177-187 (2014).
85. Winkelmann, J., Stautner, A., Samtleben, W. & Trenkwalder, C. Long-Term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov. Disord. 17, 1072-1076 (2002).
86. Schneider, R., Karakas, E., Bartsch, D. K. & Schlosser, K. The influence of parathyroidectomy on restless legs syndrome in patients with renal hyperparathyroidism. World J. Surg. 37, 2866-2871 (2013).
87. Collado-Seidel, V. et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am. J. Kidney Dis. 31, 324-328 (1998).
88. Pellecchia, M. T. et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin. Neuropharmacol. 27, 178-181 (2004).
89. de Oliveira, M. M., Conti, C. F., Valbuza, J. S., de Carvalho, L. B. & do Prado, G. F. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. Mov. Disord. 25, 1335-1342 (2010).
90. Giannaki, C. D. et al. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 85, 1275-1282 (2014).
91. Connor, J. R. et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 134, 959-968 (2011).
92. Earley, C. J. The importance of oral iron therapy in restless legs syndrome. Sleep Med. 10, 945-946 (2009).
93. Cho, Y. W., Allen, R. P. & Earley, C. J. Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Med. 14, 274-277 (2013).
94. Picchietti, D. L. et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med. Rev. 22, 64-77 (2015).
95. Fuhs, A. et al. Effects of short- and long-Term variations in RLS severity on perceived health status-The COR-study. PLoS One 9, e94821 (2014).
96. García-Borreguero, D. et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov. Disord. 27, 277-283 (2012).
97. Allen, R. P. & Earley, C. J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19, 205-213 (1996).
98. Paulus, W. & Trenkwalder, C. Less is more: pathophysiology of dopaminergic-Therapy-related augmentation in restless legs syndrome. Lancet Neurol. 5, 878-886 (2006).
99. Trenkwalder, C., Paulus, W. & Walters, A. S. The restless legs syndrome. Lancet Neurol. 4, 465-475 (2005).
100. Trenkwalder, C. et al. First 1-year real-life study to assess management of augmentation of restless legs syndrome by switching to rotigotine transdermal system [abstract]. Neurology 84 (Suppl.), P7.304 (2015).
101. Hornyak, M. & Kaube, H. Long-Term treatment of a patient with severe restless legs syndrome using intrathecal morphine. Neurology 79, 2361-2362 (2012).
102. Ross, D. A., Narus, M. S. & Nutt, J. G. Control of medically refractory restless legs syndrome with intrathecal morphine: case report. Neurosurgery 62, E263 (2008).
103. Lindvall, P., Ruuth, K., Jakobsson, B. & Nilsson, S. Intrathecal morphine as a treatment for refractory restless legs syndrome. Neurosurgery 63, E1209 (2008).
104. Nirenberg, M. J. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 30, 587-592 (2013).
105. Maestri, M. et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med. 15, 570-575 (2014).
106. Winkelmann, J. et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet. 7, e1002171 (2011).
107. Benes, H. et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J. Neurol. 258, 1046-1054 (2011).
108. Montagna, P. et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 12, 34-40 (2011).
109. Bayard, M. et al. Bupropion and restless legs syndrome: a randomized controlled trial. J. Am. Board. Fam. Med. 24, 422-428 (2011).